Innovent Biologics, Inc.
Research Innovent Biologics, Inc. (1801.HK) on Bullrun: market cap HKD 155.29B, P/E 117.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1801.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 155.29B
- P/E117.2
- Financial periodFY2025
- RevenueCNY 13.04B
- Revenue growth38.4%
- Net incomeCNY 813.57M
- Free cash flowCNY 9.32B
- Gross margin86.5%
Valuation Snapshot
latest market cap is HKD 155.29B; P/E is 117.2.
Peer valuation comparison
Latest P/E is 117.17x versus a Healthcare sector median of 21.75x (438.8% above).
Latest P/E is 117.17x versus a China median of 16.26x (620.5% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 13.04B | CNY 813.57M | CNY 9.32B | 86.5% | 0.47 | CNY 17.34B | CNY 2.82B | CNY 19.36B |
| FY2024 | CNY 9.42B | -CNY 94.63M | -CNY 418.39M | 84.0% | -0.06 | CNY 7.51B | CNY 2.83B | CNY 13.12B |
| FY2023 | CNY 6.21B | -CNY 1.03B | -CNY 1.24B | 81.7% | -0.66 | CNY 2.75B | CNY 3.62B | CNY 12.53B |
| FY2022 | CNY 4.56B | -CNY 2.18B | -CNY 3.30B | 79.6% | -1.46 | CNY 1.02B | CNY 3.23B | CNY 10.73B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 155.29B | 117.2 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Innovent Biologics, Inc.
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases.
ETFs that hold Innovent Biologics, Inc.
Innovent Biologics, Inc. is one of the ten largest holdings of 4 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| UBS Solactive China Technology UCITS ETF USD acc | 2.86% | 0.47% |
| UBS Solactive China Technology UCITS ETF hEUR acc | 2.86% | 0.50% |
| VanEck New China ESG UCITS ETF | 1.40% | 0.60% |
| UBS Solactive China Technology UCITS ETF | 2.86% | 0.50% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Innovent Biologics, Inc.'s market cap?
Innovent Biologics, Inc.'s market capitalization is HKD 155.29B.
What is Innovent Biologics, Inc.'s P/E ratio?
Innovent Biologics, Inc.'s price-to-earnings (P/E) ratio is 117.2.
What does Innovent Biologics, Inc. do?
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases.